OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

By H. Diener, Dw Dodick, S. Aurora, C. Turkel, R. DeGryse, R. Lipton, S. Silberstein, MF Brin. Cephalalgia, 2010

814 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/f4f9a3e81662f749640c38e63af30831783753e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Richard B. Lipton
2. S. Silberstein
3. H. Diener
4. D. Dodick
5. M. Brin
6. C. Turkel
7. R. Degryse
8. S. Aurora

Citations in the corpus

• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program (2010, methodology): “—Inclusion and exclusion criteria of the individual PREEMPT studies were the same and are described elsewhere.(32,33) Briefly, eligible patients were men or women aged 18-65 years with a history of migraine meeting the diagnostic criteria listed in ICHD-II (2004) Section 1, Migraine,(4) with “compli”